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Abstract
Background: Congestive heart failure (CHF) and diabetes mellitus are serious and chronic complex diseases
that commonly coexist together. The pathophysiology of the link between congestive heart failure and
diabetes is impaired glucose homeostasis that affects the myocardium at both the cellular and structural level
that eventually affects its intrinsic biochemical pathway leading to progression of the failing heart. The aim of
this study was to attempt to clarify whether glucagon-like peptide (GLP-1) infusions improve cardiac
function in congestive heart failure patients.
Methods: An exhaustive search of Medline-OVID, CINAHL, Medline-PubMed and Google Scholar using
the keywords: congestive heart failure, insulin resistance, diabetes, metabolism, GLP-1, exenatide, liraglutide,
and left ventricular function.
Relevant articles were assessed for quality using GRADE.
Results: Three studies met inclusion criteria and were included in this systematic review. A non-randomized
pilot study of 21 CHF patients with and without diabetes with 5 weeks of GLP-1 infusion that demonstrated
improved left ventricular ejection fraction (LVEF) and quality of life (QOL). A double-blind, randomized,
two-period cross-over trial of 20 CHF patients with diabetes with 6 hours of GLP-1 infusion followed by a
wash out period illustrated improved cardiac function (cardiac index, PCWP, RAP). The final study was a
non-randomized pilot study of 6 patients with diabetes with 3 days of GLP-1 infusion that showed improved
global systolic and diastolic function.
Conclusion: The above clinical studies have provided a promising impact in the improvement of cardiac
function in a failing heart. However, these studies lack randomization and are of a small sample size. Therefore,
further intense research studies are necessary to confirm these initial observations and to investigate the
underlying mechanisms and explore possible interactions with the current heart failure therapies. At this
point, the role of GLP-1 in reversing the cardiac function in the failing heart are still at its infancy, thus more
clinical trials with stronger patient important outcomes in regards to cardiovascular morbidity and mortality
as needed
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Abstract   
 
Background: Congestive heart failure (CHF) and diabetes mellitus are serious and 
chronic complex diseases that commonly coexist together.  The pathophysiology of the 
link between congestive heart failure and diabetes is impaired glucose homeostasis that 
affects the myocardium at both the cellular and structural level that eventually affects its 
intrinsic biochemical pathway leading to progression of the failing heart.  The aim of this 
study was to attempt to clarify whether glucagon-like peptide (GLP-1) infusions improve 
cardiac function in congestive heart failure patients.   
 
Methods:  An exhaustive search of Medline-OVID, CINAHL, Medline-PubMed and 
Google Scholar using the keywords: congestive heart failure, insulin resistance, diabetes, 
metabolism, GLP-1, exenatide, liraglutide, and left ventricular function. 
Relevant articles were assessed for quality using GRADE.   
 
Results:  Three studies met inclusion criteria and were included in this systematic 
review.  A non-randomized pilot study of 21 CHF patients with and without diabetes with 
5 weeks of GLP-1 infusion that demonstrated improved left ventricular ejection fraction 
(LVEF) and quality of life (QOL).  A double-blind, randomized, two-period cross-over 
trial of 20 CHF patients with diabetes with 6 hours of GLP-1 infusion followed by a wash 
out period illustrated improved cardiac function (cardiac index, PCWP, RAP).  The final 
study was a non-randomized pilot study of 6 patients with diabetes with 3 days of GLP-1 
infusion that showed improved global systolic and diastolic function.   
 
Conclusion: The above clinical studies have provided a promising impact in the 
improvement of cardiac function in a failing heart.  However, these studies lack 
randomization and are of a small sample size.  Therefore, further intense research studies 
are necessary to confirm these initial observations and to investigate the underlying 
mechanisms and explore possible interactions with the current heart failure therapies.  At 
this point, the role of GLP-1 in reversing the cardiac function in the failing heart are still 
at its infancy, thus more clinical trials with stronger patient important outcomes in 
regards to cardiovascular morbidity and mortality as needed  
 
Keywords: congestive heart failure, insulin resistance, diabetes, metabolism, GLP-1, 
exenatide, liraglutide and left ventricular function 
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Efficacy of GLP-1 Infusion in Congestive Heart Failure Patients on Myocardial 
Function 
BACKGROUND 
 Congestive heart failure (CHF) and diabetes mellitus are a serious and chronic 
complex disease that commonly coexists together.  Despite the use of many current 
pharmacological interventions in the treatment of congestive heart failure, there has not 
been an improvement in morbidity and mortality rates.  It is estimated that 5.7 million 
people in the United States have CHF with about half of them dying within 5 years of 
diagnosis.1  Heart failure has costs to the nation $34.4 billion each year, which includes 
the cost of health care services, medications, and lost productivity. 2 Several factors have 
been linked to congestive heart failure, but diabetes mellitus has been the major 
cornerstone in the progression of the failing heart.  The Framingham study3 was the first 
to show an increased risk of CHF in patient with diabetes mellitus, with an incidence of 
CHF that showed a 4-fold and 8-fold increase in men and women with diabetes mellitus, 
respectively, compared with those without diabetes mellitus.  In the National Health and 
Nutritional Examination Survey (NHANES), diabetes mellitus was independently 
associated with an increased risk of CHF (RR 1.85; 95% CI=1.51, 2.28; p<0.01). 3  
 The pathophysiology behind the failing heart is the underlying impaired glucose 
homeostasis that eventually affects the myocardium at the cellular, structural and 
molecular level and various biological pathways regulating to these changes.   Patients 
with CHF display a variety of metabolic abnormalities ranging from abnormal glucose 
intolerance to overt diabetes.4 Moreover, studies 5,6 on patients with diabetes have 
demonstrated that there are several structural and cellular changes within the heart that is 
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related to glucose intolerance.  In fact, the impaired glucose uptake caused by diabetes 
mellitus may be particularly deleterious in patients with concomitant coronary artery 
disease (CAD).  Having these disease together is associated with a shift in the myocardial 
metabolism from free fatty acids (FFA) to glucose and glycolysis.7,8 Furthermore, left 
ventricular functions are inversely correlated with myocardial FFA oxidation in patients 
with heart failure (HF).  Based on the pathophysiology of the impact of diabetes mellitus 
in the progression of the failing heart, it clearly suggests that by preventing diabetes or 
incorporating  diabetes mellitus (DMII) treatment should help to reduce both the 
morbidly and mortality of patient in CHF.    
 New pharmaceutical agents in the management of DMII, glucagon-like peptide 1 
(GLP-1) agonists (such as liragluide and exenatide) have been studied in animals which 
demonstrated the possibility of a significant impact in the improvement of cardiac 
function in the setting of CHF patients.9 Glucagon-like peptide 1 (GLP-1) is an incretin 
that is released when blood glucose levels are above fasting levels.9 GLP-1 receptor 
agonists favors glycemic control by decreasing postprandial sugars.  This is important to 
note as multiple studies10,11-14  have shown hyperglycemia to be an independent risk 
factor associated with poor outcomes in the setting of CHF.  Furthermore, GLP-1 
receptor agonists have extra-glycemic effects, including promoting beta cell proliferation, 
slowing gastric emptying, increasing satiety, and promoting weight loss.  This results in 
the reduction of postprandial glycemic levels, improvement of endothelial function, a 
decrease in systolic blood pressure (BP), and improvement in the lipid profile. 
 By taking into consideration, the characteristics of GLP-1 receptor agonists along 
with its cardio protective role proven in the animal models, has allowed one to consider 
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these drugs as an alternative use in the setting of CHF patients with diabetes. The purpose 
of this review was to attempt to clarify whether GLP-1 agonist infusions improve cardiac 
markers in setting of CHF in the humans. 
METHODS 
 An exhaustive search of Medline-OVID, CINAHL, Medline-PubMed and Google 
Scholar using the keywords: GLP-1, exenatide, liraglutide, diabetes, metabolism, heart 
failure, insulin resistance, ejection fraction, cardiac output, cardiac index, mortality, right 
atrial pressure, and pulmonary capillary wedge pressure. The articles that were obtained 
through this search were screened for additional relevant articles pertaining to the 
graduate project title.  The inclusion criteria was comprised of studies investigating the 
improvement of myocardial function of GLP-1 in diabetic and non-diabetic patients in 
the setting of CHF using left ventricular ejection fraction (LVEF), cardiac index (CI), 
cardiac output (CO), Pulmonary capillary wedge pressure (PCWP), right atrial pressure 
(RAP), and quality of life (QOL).  Excluded were animal studies and studies evaluating 
GLP-1 receptor agonists in the setting of myocardial infarction and ischemia.  All the 
relevant articles were assessed for quality using GRADE. 15  
 
RESULTS 
 The initial result of the search yielded 14 articles for review.  From this search, 
three articles met inclusion articles.16-18 See Table 1.  A search on the NIH clinical trials 
website revealed there is one current on-going  trial.19 involving liraglutide (GLP-1 
agonist drug) and heart failure in type 2 diabetes. 
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Sokos et al 
 This small (n=21), single center, randomized, pilot study16 was designed to 
evaluate the efficacy of a 5-week infusion of a GLP-1 receptor agonist (at 2.5 
pmol/kg/min) along with current therapy in CHF patients.  The first 12 patients to 
complete the consent form and be screened for inclusion and exclusion criteria were 
given a GLP-1 receptor agonist (7-36 amide, Restoragen, Inc., Lincoln NE) and the 
following nine individuals were placed on placebo.16 
   Patients were excluded from the study if they had: 1) heart failure due to or 
associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial 
disease, amyloidosis, or active myocarditis; 2) conventional cardiac revascularization 
procedure, LV reduction procedure, or cardiomyoplasty within 30 days prior to 
enrollment; 3) evidence of intrinsic hepatic disease  defined as liver enzyme values 
greater than 5 times the upper limit of normal, a prolonged prothrombin time in the 
absence  of systemic anticoagulation therapy at the time of screening; 4) serum creatinine 
greater than 3.5mg/dl or long-term dialysis; 5) type 1 diabetes mellitus; 6) presence of a 
condition other than heart failure that would limit survival to less than 1 year; or 7) 
hospitalization for acute decompensation of CHF in the past 60 days.16 In the study, all 
the patients were on a standard stable heart failure medication regime.  The study was to 
test the efficacy of a 5-week infusion of GLP-1 agonist (2.5 pmol/kg/min) along with 
added therapy in CHF patients. 16  
 The primary outcome was to evaluate the left ventricular (LV) function at rest 
assessed by 2-dimensional ECHO and exertion by VO2 max measured by 
cardiopulmonary exercised treadmill test.  The secondary outcome was to measure the 
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QOL by a 6-minute walk distance and Minnesota Living and Heart Failure 
Questionnaire.16 
 Evaluation of the LVEF thru Simpson’s method on standard 2-dimenional images 
was analyzed by qualified echocardiographer that was blinded in the study.  The authors 
reported that 16 LVEF was (21 ± 3% to 27 ± 3%; p<0.001) in the GLP-1 agonist treated 
patients vs. unchanged in the control group (21 ± 4% to 22  ± 4%). 
 Evaluation of the secondary outcomes were as follows: 6-minute walk distance 
improved in the treatment group (232 ± 15m to 286 ± 12m; p<0.001) vs. was unchanged 
in the control group (233 ± 21 to 258 ± 21m), VO2 max improved from 10.8 ± 0.9 to 
13.9 ± 0.6 ml/kg/min (p<0.001) in the treatment group vs. was unchanged in the control 
group (13.3 ± 0.9 to 13 ± 1.0ml/kg/min), and  QOL improved in the treatment group (64 
± to 44 ± 5, p<0.01) vs. was unchanged in the control group (52 ± 12 to 46 ±  12). 16  See 
Table 2.   
 Adverse events were also reported.  After 17 days of continuous infusion of GLP-
1 receptor agonist in a patient with class IV heart failure secondary to severe aortic 
stenosis, died on the 18th day of this study.16   In addition, there were two hospitalizations 
in each group with non-sustained ventricular tachycardia and one episode of atrial 
fibrillation in the GLP-1 receptor agonist treated group.16 The most common adverse 
effects in the treatment group was nausea and constipation which occurred (eight 
episodes) in five patients.  Additionally, nine episodes of hypoglycemia (glucose 50-70 
mg/dl) in 4 GLP-1 treated patients and four episodes of hypoglycemia in two control 
patients.16 
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Nathanson et al 
 The purpose of this study determines whether exenatide improves hemodynamic 
function in patients with type 2 diabetic patients with congestive heart failure.  Within 
237 patients screened, 20 male type 2 diabetic patients participated in this double-blind, 
randomized crossover trial17 and were allocated (sequentially numbered) to intravenous 
infusions during two consecutive days with 1) exenatide (at 0.12 pmol/kg/min) and (2) 
placebo provided by Eli Lilly Amyliin Alliance Indianapolis, IN, USA  for 6 hours 
followed by a washout period for 18 hours  at Stockholm South Hospital, Sweden.17  
 Furthermore, the study populations were given their regular heart failure 
medication such as angiotensin-converting enzyme or angiotensin-II receptor antagonist, 
beta blockers (except one patient) and diuretics along  in the morning (07:00 hours) and 
evening (19:00 hours), except for prandial insulin, metformin, and sulfonylurea that were 
withheld during the study protocol.17  Participants were confined to the intensive care unit 
during the whole study period, including 6 hours in a supine position during 
measurements.  Both operator and patients were blinded to the assignment.17  
 Patients were excluded from the study if they had: 1) type 1 diabetes, 2) ongoing 
treatment with inotropic agents, 3) acute coronary syndrome or documented acute MI 
within the previous 8 weeks, 4) active myocarditis, 5) significant aortic stenosis or 
mitral/tricuspid regurgitation, 6) symptomatic primary pulmonary disease, 7) ventricular 
arrhythmias, 8)  second- or third-degree atrioventricular block, 9)  implanted cardioverter 
defibrillator or biventricular pacemaker, 10)  supine systolic blood pressure <85 or >200 
mmHg, 11) primary renal or hepatic impairment (estimated GFR [eGFR] <30 ml/min, 
aspartate aminotransferase/alanine aminotransferase >2 times upper limit of normal), 12) 
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hypokalemia (<3.5 mmol/l) or hyperkalemia (>5.5 mmol/l), 13) significant anemia (Hb 
,100 g/l), 14)  pregnancy, and 15) previous treatment with GLP-1 receptor  agonist or a 
DPP-4 inhibitor.17   
 The primary endpoints were defined as an  increase in cardiac index (CI) or a 
decrease in pulmonary capillary wedge pressure (PCWP) of ≥ 20% that were determined 
by cardiac catherization (pulmonary artery thermodilution cathers 7.5 F; AH-05050, 
Arrow International, Bernville, PA, USA) and were used to calculate CO from the 
modified Steward-Hamilton equation. 17 
 The authors reported statistically significant improvements in all cardiac measures 
in the participants. See Table 3.  Specifically, cardiac index increased at 3 and 6 hours by 
23% and 17% during exenatide infusion vs. -1% and -5% during placebo (p = 0.003); 
and heart rate (HR) increased at 3, and 6 hours by 21% and 29% beats per min (bpm), 
during exenatide infusion vs. 2% and 8% bpm, during placebo (p = 0.006); and PCWP 
decreased at 3 and 6 h by -8% and -15% mmHg, during exenatide infusion vs. 6% and 
8% mmHg, during placebo (p = 0.001). There were nine patients that had adverse side 
effects of the drug (six, nausea; two, increased HR; one, increased systolic blood 
pressure). 17 
 
Thrainsottir et al 
 The purpose of this study18 was to assess the viability and safety of three days' 
infusion of recombinant GLP-1 receptor agonist (at 4 pmol/kg/min, or in the case of 
nausea during the infusion at 3 pmol/kg/min) in an open observational study in six 
hospitalized male patients with type 2 diabetes and CHF.  The authors 18 included 
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assessment of metabolic control (by measuring plasma concentration of free fatty acids, 
glucagon, insulin, C-peptide) and myocardial function (by measuring rate pressure, 
PCWP, RAP, and heart rate). See Table 4. The rate pressure is a measure of the stress put 
on the cardiac muscle based on the cardiac muscle based on the number of times it needs 
to beat per minute (HR) and the arterial blood pressure that it is pumping against 
(SBP).20These measures were recorded at rest upon awaking in the morning and at stress 
post exercising.  There were no major complications of the infusion, and all patients 
completed the study protocol.18 
 The authors reported an overall reduction in the rate pressure during the study 
period both at rest from 9225 bpm*mmHg on day 1 to 8658 bpm*mmHg on day 4.  
Similarly, at stress the rate pressure reduced from  17136 bpm*mmHg on day 1 to 16170 
bpm*mmHg on day 4.  Furthermore, there was a significant reduction in resting heart rate 
at day 2 and 3, but was minimal at day 4.  Similarly, there was a slight trend towards 
decreasing systolic pressure and increase diastolic pressure.18  
 Briefly, individuals in this study not only benefited from short-term GLP-1 
receptor agonist infusion on the myocardial parameters but the average fasting blood 
glucose decreased significantly on day two but increased somewhat after that. The plasma 
concentrations of free fatty acids were decreased in four of the two patients. The average 
plasma concentrations (mg/dl) on day 1 vs. day 4 were as follows:  for glucagon were 20 
vs. 22.2, insulin 10.5 vs. 6.3, C-peptide 1.53 vs. 1.22 and free fatty acids 0.63 vs. 0.28.18 
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DISCUSSION 
 Hence for patients with heart failure and diabetes, GLP-1 receptor agonist could 
be considered as an alternative when other glucose lowering drugs such as insulin and 
thiazolidinediones are associated with fluid retention, and metformin is contraindicated in 
patients with significant renal insufficiency. (CITE) In the setting of CHF patients, Soko 
et al16 demonstrated that long term GLP-1 receptor agonist treatment  (5 weeks) in both 
diabetic and normoglycemic chronic heart failure patients (New York Heart Association 
class III and IV) to significantly improve LV ejection fraction,  myocardial oxygen 
consumption, and functional status, whereas no effect from GLP-1 receptor agonist was 
observed in patients with normal cardiac function.16Additionally, this study 16showed 
improvement in glycemic control and less use of inotropic and vasoactive infusions with 
few arrhythmias in GLP-1 receptor agonist treated patients and reduction of B-type 
natriuretic peptide (BNP)  in the GLP-1 treated (289 ± 129; 5 weeks: 218 ±  102pg/ml) 
vs. control group (296 ±  129; 5 weeks: 285 ±  152 pg/ml).  Despite the fact that Sokos et 
al 16 showed promising results in the improvement of the hemodynamic parameters and 
no side effects of hypoglycemia were reported, the study was limited to its non-
randomized small sample size with no control groups methodology.  Furthermore, 
individuals were obese (BMI>30) thus, the results may not be applicable to heart failure 
patients with cachexia.   
 Furthermore, the other study that evaluated GLP-1 receptor agonist use in long 
term, Thrainsottir et al18 showed improvement in a different set of cardiac parameters in 
the setting of diabetic patients with CHF.  The rate pressure is a crucial hemodynamics 
parameter in the management of CHF patients where it is a measure that rates the fluid 
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overload when the heart is trying to utilize its energy to pump against this high resistance 
pressure to pump blood out of the ventricles to be distributed to the entire body.  The rate 
pressure was improved both at rest and stress along with moderate improvement in heart 
rate and systolic and diastolic function.18  
 In contrast, in a short-term study by Nathanson et al study17 improvements were 
observed using different hemodynamic cardiac parameters, specifically the cardiac index 
and pulmonary capillary wedge pressure.  In this study,17 there was an increase in the 
cardiac index that was directly linked with an increase in heart rate without any change in 
SV, suggestion of a positive chronotropic effect of exenatide.17 One way to minimize the 
work load on the heart is to increase cardiac index through elevations of inotropy and 
chronotropy effect. 17 This is in contrast to rodent studies, in which exenatide dose-
dependently induced chronotropic effects paralleled by pressor action.21 The increase in 
heart rate noted prior to fasting and with the infusion of exanatide, was contributed 
because of the increase levels of  non-esterified fatty acids (NEFA) levels (measured by 
using NEFA-HR kit Wako Chemicals Neuss, Germany on a Thermo T20xti instrument 
Kone, Espoo, Finland) that leads to lipotoxicity and insulin resistance and this effect is 
more pronounced on the myocardial metabolism in female than male.17  Despite, the 
increase in HR, which can be detrimental in the setting CHF patients there were no 
symptoms of worsening of heart failure or other serious adverse events observed in the 
study.   Furthermore, in this study17, there was a substantial decreased in PCWP and right 
atrial pressure (RAP) following exenatide infusion having a direct vasodilatory effect in 
the vessel beds.  
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 Although, these clinical studies16-18 have encourage the potential use of GLP-
1receptor agonists in the treatment of heart failure, they lack randomization and were of a 
small sample size.  Moreover, Trainsdottir et al18 lacked a control group.   Overall, these 
flaws result in an overall GRADE of very low quality of evidence.  See Table 1.  It is 
clear that significant further research is required to confirm these initial observations, 
investigating the underlying mechanisms and exploring possible interactions with current 
heart failure therapies.  Currently, in progress is a study19 to determine whether GLP-1 
receptor analogue liraglutide improves heart function after 18 weeks of liraglutide + 
metformin, compared with glimepride + metformin, using tissue Doppler 
echocardiography.  This study and hopefully many more in the future may provide 
answers to many of the previous questions and investigations on the role of GLP-1 
receptor agonists in the setting of CHF on myocardial function. 
 
CONCLUSION 
 Undoubtedly, GLP-1 receptor agonists in these clinical studies have 
proved beneficial effects on the metabolic and hemodynamic function in CHF patients.  
However, there are several important differences between these clinical studies that 
supported GLP-1 receptor agonist in the role of cardiac function in terms of different 
cardiac parameters tested, amount of dose and duration with the GLP-1 receptor agonist 
and methodology.  Nevertheless, GLP-1 receptor agonists have also shown improvement 
in the treatment of hyperglycemia associated with type 2 diabetes mellitus.  Since the 
overall quality of evidence is very low, further research is necessary in order to identify 
the role that GLP-1 receptor agonists should play in the management of patients with 
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both diabetes and CHF.  
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Table 1. GRADE Quality Assessment 
 
 
a Small sample size and lacked randomization. Also, Trainsdottir et al lacks control group 
  
Quality Assessment 
Design 
Number 
of 
patients 
Infusion time Limitations Indirectness Imprecision Inconsistency Other 
considerations Quality 
Sokos et al16 
Non-
randomized 
pilot study 
21 
5 weeks of 
GLP-1 
infusion @ 
2.5 
pmol/kg/min 
Very 
serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
Selection bias 
(obese 
individuals) 
Very 
Low 
Nathanson et al17 
Single center, 
randomized 
two-period 
cross over 
double-blind 
study 
20 
6 hr of GLP-
1 infusion @ 
0.12 
pmol/kg/min 
followed by 
a washout 
period of 18 
h 
Very 
serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
Study was 
funded by Eli 
Lilly Amylin 
Alliance USA 
Very 
Low 
Thrainsdottir et al18 
Non-
randomized 
pilot study 
6 
3 days of 
GLP-1 
infusion @ 4 
pmol/kg/min 
Very 
serious 
limitationsa 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies none 
Very 
Low 
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Table 2. Sokos et al16 Summary of Findings 
 
Outcome GLP-1 receptor agonist 
group 
Control group P-Value 
Baseline Post treatment Baseline Post 
treatment 
LVEF 21 ± 3% 27 ± 3% 21+/- 4% 22 +/-4%) P<0.001 
6-minute walk distance (m) 232 ± 15 286± 12 233 ± 21 258 ± 21 P<0.001 
VO2 max (ml/kg/min) 10.8± 0.9 13.9±0.6 13.3 ± 
0.9 
13 ±1.0 P<0.001 
 
Table 3. Nathanson et al16 Summary of Findings 
 
Outcome GLP-1 receptor agonist 
group 
Placebo group P-Value 
 3 hours 6 hours 3 hours 6 hours 
Cardiac index (l/min/m2) 
2.2 ± 0.1  2.1 ± 0.1  1.8 ± 
0.1  
1.9 ± 
0.1  
P=0.003 
PCWP (mmHg) 13.6 ± 2 12.6 ± 2 17 ± 1 17.4 ± 2 P=0.001 
RAP (mm Hg) 6.1 ± 1 6.6 ± 1 8.8 ± 1 7.9 ± 1 P=0.03 
Heart rate (bpm) 88 ± 4 94 ± 5 75 ± 4 79 ± 4 P=0.006 
 
Table 4. Thrainsottir et al17 Summary of Findings 
 
Outcome Day 1 Day 4 
 HR 
(b/min) 
 BP 
(mmHg) 
bRPP 
(mmHg *b/min) 
HR 
(b/min) 
BP 
(mmHg) 
RPP 
(mmHg*b/min) 
Morning, at rest 
75 123 9255 74 117 8658 
Stress, at exercise 112 153 17136 110 147 16170 
 
bRPP= rate pressure product (systolic blood pressure x heart rate) 
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